Humacyte, Inc. (HUMA) intrinsic value & 10-year financials
Humacyte, Inc. (HUMA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 6.5% a year to $2.0M, with an average return on invested capital of 315.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.43
- Market cap
- $67.9M
- Revenue (FY2025)
- $2.0M
- Revenue growth (7-yr CAGR)
- 6.5%
- ROIC (10-yr avg)
- 315.7%
- Free cash flow (FY2025)
- -$105.9M
HUMA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $2.0M | -$40.8M | -$0.26 | -$105.9M | -5306.0% | 315.9% |
| FY2024 | $0 | -$148.7M | -$1.26 | -$99.7M | — | 171.4% |
| FY2023 | $0 | -$110.8M | -$1.07 | -$75.6M | — | 315.8% |
| FY2022 | $1.6M | -$12.0M | -$0.12 | -$72.2M | -5404.3% | 297.3% |
| FY2021 | $1.3M | -$26.5M | -$0.66 | -$81.4M | -6429.8% | 1027.0% |
| FY2020 | $1.5M | -$66.5M | -$1.65 | -$55.9M | -4332.7% | -233.0% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Humacyte, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Humacyte, Inc. has historically struggled to out-earn its cost of capital, averaging just 3.2% ROIC.
Humacyte, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Humacyte, Inc. is modeled at 6.5% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-4.80 per share.